Boston Business Journal H3 Biomedicine to Begin Trials of First-Ever Gene-Splicing Cancer Drug Kendall Square-based cancer biotech H3 Biomedicine, created five years ago by Japanese drug firm Eisai, will bring its first drug… Read More
May 11, 2016 H3 Biomedicine Receives FDA Acceptance for Investigational New Drug Application Novel Hematologic Compound Bolsters Company’s Emerging Drug Pipeline H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member… Read More